Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Design Therapeutics, Inc. (DSGN)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$9.67-9.03%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for DSGN yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Advance clinical development of DT-216P2 for Friedreich ataxia | The company keeps advancing its clinical trial for DT-216P2. | Intact | trial data fails to show safety or clinical benefit next year | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 3 of 3 supplied quarters. Management reported: “Design expects to provide an update on its registrational plans in the fourth quarter of 2026, with data following 12 weeks of treatment expected in the first quarter of 2027.” “• Next Steps and Expected Milestones: Design expects to provide an update on its registrational plans in the fourth quarter of 2026, with data following 12 weeks of treatment expected in the first quarter of 2027.” |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-development business, not an established earnings compounder. The long-term thesis is in a watch state: management is advancing DT-216P2, but recent financial performance is weak and the evidence snapshot has low confidence.
The evidence provided does not include valuation measures or a clear account of what the market already assumes, so whether DSGN is cheap or expensive versus peers cannot be assessed. The muted price reaction to recent events does not by itself show what expectations are priced in.
Near term, losses and cash use are likely to remain central: quarterly net loss and research spending rose, while cash reserves declined but were reported to support development into 2029. Management reports ongoing trial progress and expects a 12-week data update in Q1 2027 and a registrational update in Q4 2026; recent earnings beats are positive signals, but performance remains well below its industry cohort.
Over the multi-year view, the key swing factor is whether DT-216P2 produces useful clinical evidence while management keeps spending and cash burn controlled. Near term, weakening jobs data could weigh on cyclical names, while continued strength or weakness among VRTX, REGN, and MRNA may signal whether the broader Healthcare sector tailwind persists.
For the next 1 to 3 years, DSGN remains a high-risk clinical-development story with meaningful cash runway, but its thesis depends on trial progress and disciplined spending. Confidence is low, and recent financial performance remains weak. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Maintain leadership and governance stability | A supporting condition in Design Therapeutics, Inc.'s published investment case. The stated target is No major unexpected leadership departures in next 4 quarters. | Intact | unexpected loss of key executives or directors | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Manage operating expenses and cash burn | Operating losses and cash burn are high but expected in this phase. | Intact | operating losses or cash burn worsen beyond negative $20M per quarter | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 3 of 3 supplied quarters. Management reported: “• Cash Position: Cash, cash equivalents and investment securities were $208.6 million as of September 30, 2026.” “• Cash Position and Operating Runway: Cash, cash equivalents and investment securities were $222.8 million as of March 31, 2026, which the company expects to fund its planned operations into 2029.” Operating cash flow was $-16.431 million in 2026-Q1. Delivery assessment Nov 5, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.64 → $-1.59 · observed estimates
$0.20B → $0.20B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.64 | $204,776,000 | 5 / 7 |
| 2026-07-25 | $-1.64 | $0 | 7 / 7 |
| 2026-07-26 | $-1.64 | $0 | 7 / 7 |
| 2026-07-27 | $-1.64 | $204,776,000 | 5 / 7 |
| 2026-07-28 | $-1.64 | $0 | 7 / 7 |
| 2026-07-29 | $-1.64 | $0 | 7 / 7 |
| 2026-07-30 | $-1.64 | $0 | 7 / 7 |
| 2026-07-31 | $-1.64 | $0 | 7 / 7 |
| 2026-08-01 | $-1.64 | $204,776,000 | 5 / 7 |
| 2026-08-02 | $-1.64 | $0 | 7 / 7 |
| 2026-08-03 | $-1.64 | $0 | 7 / 7 |
| 2026-08-04 | $-1.64 | $0 | 7 / 7 |
| 2026-08-05 | $-1.61 | $0 | 7 / 7 |
| 2026-08-06 | $-1.58 | $204,776,000 | 5 / 7 |
| 2026-08-07 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-08-08 | $-1.61 | $0 | 7 / 7 |
| 2026-08-09 | $-1.61 | $0 | 7 / 7 |
| 2026-08-10 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-08-11 | $-1.59 | $0 | 7 / 7 |
| 2026-08-12 | $-1.59 | $0 | 7 / 7 |
| 2026-08-13 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-08-14 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-08-15 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-08-16 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-08-17 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-08-18 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-08-19 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-08-20 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-08-21 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-08-22 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-08-23 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-08-24 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-08-25 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-08-26 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-08-27 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-08-28 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-08-29 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-08-30 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-08-31 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-09-01 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-09-02 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-09-03 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-09-04 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-09-05 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-09-06 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-09-07 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-09-08 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-09-09 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-09-10 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-09-11 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-09-12 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-09-13 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-09-14 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-09-15 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-09-16 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-09-17 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-09-18 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-09-19 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-09-20 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-09-21 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-09-22 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-09-23 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-09-24 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-09-25 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-09-26 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-09-27 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-09-28 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-09-29 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-09-30 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-10-01 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-10-02 | $-1.56 | $204,776,000 | 5 / 7 |
| 2026-10-03 | $-1.59 | $204,776,000 | 5 / 7 |
| 2026-10-04 | $-1.59 | $204,776,000 | 5 / 7 |
| 2026-10-05 | $-1.59 | $204,776,000 | 6 / 8 |
| 2026-10-06 | $-1.59 | $204,776,000 | 6 / 8 |
| 2026-10-07 | $-1.59 | $204,776,000 | 6 / 8 |
| 2026-10-08 | $-1.59 | $204,776,000 | 6 / 8 |
| 2026-10-09 | $-1.59 | $204,776,000 | 6 / 8 |
| 2026-10-10 | $-1.59 | $204,776,000 | 6 / 8 |
| 2026-10-11 | $-1.59 | $204,776,000 | 6 / 8 |
| 2026-10-12 | $-1.59 | $204,776,000 | 6 / 8 |
| 2026-10-13 | $-1.59 | $204,776,000 | 6 / 8 |
| 2026-10-14 | $-1.59 | $204,776,000 | 6 / 8 |
| 2026-10-15 | $-1.59 | $204,776,000 | 6 / 8 |
| 2026-10-16 | $-1.59 | $204,776,000 | 6 / 8 |
| 2026-10-17 | $-1.59 | $204,776,000 | 6 / 8 |
| 2026-10-18 | $-1.59 | $204,776,000 | 6 / 8 |
| 2026-10-19 | $-1.59 | $204,776,000 | 6 / 8 |
| 2026-10-20 | $-1.59 | $204,776,000 | 6 / 8 |
| 2026-10-21 | $-1.59 | $204,776,000 | 6 / 8 |
| 2026-10-22 | $-1.59 | $204,776,000 | 6 / 8 |
| 2026-10-23 | $-1.59 | $204,776,000 | 6 / 8 |
| 2026-10-24 | $-1.59 | $204,776,000 | 6 / 8 |
| 2026-10-25 | $-1.59 | $204,776,000 | 6 / 8 |
| 2026-10-26 | $-1.59 | $204,776,000 | 6 / 8 |
| 2026-10-27 | $-1.59 | $204,776,000 | 6 / 8 |
| 2026-10-28 | $-1.59 | $204,776,000 | 6 / 8 |
| 2026-10-29 | $-1.59 | $204,776,000 | 6 / 8 |
| 2026-10-30 | $-1.59 | $204,776,000 | 6 / 8 |
| 2026-10-31 | $-1.59 | $204,776,000 | 6 / 8 |
| 2026-11-01 | $-1.59 | $204,776,000 | 6 / 8 |
| 2026-11-02 | $-1.59 | $204,776,000 | 6 / 8 |
| 2026-11-03 | $-1.59 | $204,776,000 | 6 / 8 |
| 2026-11-04 | $-1.59 | $204,776,000 | 6 / 8 |
| 2026-11-05 | $-1.59 | $204,776,000 | 6 / 8 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 8 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 1 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.